Mustang Bio, Inc. (MBIO)

NASDAQ: MBIO · IEX Real-Time Price · USD
0.401
-0.020 (-4.66%)
At close: Jul 12, 2024, 4:00 PM
0.405
+0.004 (0.97%)
After-hours: Jul 12, 2024, 7:59 PM EDT
-4.66%
Market Cap 13.68M
Revenue (ttm) n/a
Net Income (ttm) -40.10M
Shares Out 34.10M
EPS (ttm) -4.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,407,055
Open 0.421
Previous Close 0.421
Day's Range 0.400 - 0.434
52-Week Range 0.128 - 5.715
Beta 1.89
Analysts Strong Buy
Price Target 12.00 (+2,891.03%)
Earnings Date Aug 12, 2024

About MBIO

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare g... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Manuel Litchman M.D.
Employees 80
Stock Exchange NASDAQ
Ticker Symbol MBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for MBIO stock is "Strong Buy." The 12-month stock price forecast is $12.0, which is an increase of 2,891.03% from the latest price.

Price Target
$12.0
(2,891.03% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Diamond Equity Research Releases Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB)

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Bioscience...

Other symbols: ENVB
16 days ago - GlobeNewsWire

Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical bre...

23 days ago - GlobeNewsWire

Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WORCESTER, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical bre...

24 days ago - GlobeNewsWire

Why are Mustang Bio shares (MBIO) up almost 500%?

The Mustang Bio stock price closed on a high yesterday, trading at $0.75. The pharmaceutical company has gone vertical in the past 24 hours, climbing 476.9% to go from $0.13 to $0.75 in a single day.

26 days ago - Invezz

Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?

Penny stock Mustang Bio Inc MBIO shares are trading higher on a strong session volume of 90 million versus an average volume of 3.17 million, as per data from Benzinga Pro.

27 days ago - Benzinga

Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy

Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months

27 days ago - GlobeNewsWire

Mustang Bio Announces Closing of $4 Million Public Offering

Potential Additional Gross Proceeds Upon Cash Exercise of Warrants of Up to $12 Million Potential Additional Gross Proceeds Upon Cash Exercise of Warrants of Up to $12 Million

2 months ago - GlobeNewsWire

Mustang Bio Announces Pricing of $4 Million Public Offering

WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical br...

2 months ago - GlobeNewsWire

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth...

3 months ago - GlobeNewsWire

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical br...

4 months ago - GlobeNewsWire

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma

MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively

4 months ago - GlobeNewsWire

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

WORCESTER, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical bre...

6 months ago - GlobeNewsWire

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Data showed favorable safety profile, complete response rate and durability in the treatment of patients with relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma

7 months ago - GlobeNewsWire

Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cel...

8 months ago - GlobeNewsWire

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Updated interim data from Mustang's multicenter Phase 1/2 clinical trial demonstrate favorable safety and efficacy profile of MB-106 in heavily pre-treated lymphoma patients Updated interim data from ...

9 months ago - GlobeNewsWire

Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WORCESTER, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical bre...

9 months ago - GlobeNewsWire

Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WORCESTER, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical bre...

9 months ago - GlobeNewsWire

Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

MB‐101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) are separately well tolerated in patients with recurrent GBM in ongoing Phase 1 clinical trials; preclinical data suppor...

9 months ago - GlobeNewsWire

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

WORCESTER, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in ce...

11 months ago - GlobeNewsWire

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

Initial data show clinical responses from four of four indolent lymphoma patients, including complete response in follicular lymphoma patient previously treated with CD19 CAR-T cell therapy

11 months ago - GlobeNewsWire

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cel...

11 months ago - GlobeNewsWire

Mustang Bio to Participate in Two August 2023 Investor Conferences

WORCESTER, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cel...

1 year ago - GlobeNewsWire

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

Transaction and reduction in operating expenses enhance Mustang's cash position Transaction and reduction in operating expenses enhance Mustang's cash position

1 year ago - GlobeNewsWire

Mustang Bio Announces Participation in Upcoming Scientific Meetings

Management team to speak at 2nd In Vivo Engineering of Therapeutic Cells Summit and 8th Annual CAR-TCR Summit Management team to speak at 2nd In Vivo Engineering of Therapeutic Cells Summit and 8th An...

1 year ago - GlobeNewsWire

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

10 out of 20 patients remain in complete remission for more than a year 95% overall response rate (ORR) and 80% complete response (CR) rate across all patients; 100% ORR and 91% CR with higher dose le...

1 year ago - GlobeNewsWire